MycoDelens (MD) is a patented antimicrobial formulation enhancing antifungal efficacy and reducing drug resistance. Safe for topical use, it synergizes with clotrimazole against resistant Candida species, preventing biofilm formation and resistance development.
MycoDelens (MD) is an innovative, patented antimicrobial formulation designed to combat resistant fungal pathogens. With a water-based composition of less than 1% cetrimonium chloride (CTAC) and diethylenetriaminepentaacetic acid (DTPA), MD is both safe and effective. It is particularly promising for addressing vaginal infections caused by resistant strains of Candida and Trichophyton species. MD works as a monotherapy and enhances the efficacy of clotrimazole, a common antifungal, by preventing the emergence of drug resistance. Its compatibility with other topical products like Vagisil wash makes it versatile for inclusion in various antifungal treatments.
Currently at TRL 4, MycoDelens has demonstrated efficacy in laboratory settings against multi-drug resistant fungal pathogens. Future validation involves characterizing its activity with clotrimazole, evaluating resistance impact, and assessing anti-biofilm efficacy. These studies aim to confirm its synergistic potential and readiness for broader clinical applications.
New Mexico Tech is a STEM-focused public research university in Socorro with an applied, field-scale research profile. Its Energetic Materials Research and Testing Center runs expansive test ranges adjacent to campus for research, evaluation, and training. The Petroleum Recovery Research Center and the New Mexico Bureau of Geology and Mineral Resources provide industry-facing labs, data, and services, while a co-op program links employers to student talent. Research is supported by competitive federal funding from agencies such as the National Science Foundation, Department of Energy, and Department of Defense. An Office of Innovation Commercialization and a university research park support IP, licensing, and startup formation.